Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00979459 | A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED) | PHASE1 | COMPLETED | 12 | — | — | Sep 1, 2009 | Dec 1, 2009 | Feb 5, 2016 | - | — |
AUC (0-infinity) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for two formulations of MK-1006, FCT and DFC
Maximum plasma concentration for 2 formulations of MK-1006, FCT and DFC
| Arm | Type | Description |
|---|---|---|
| MK-1006 80 mg DFC | EXPERIMENTAL | Participants received a single dose of four 20 mg dry filled capsules of MK-1006 |
| MK-1006 80 mg FCT | EXPERIMENTAL | Participants received a single dose of two 40 mg film coated tablets of MK-1006 |
| Name | Type | Description |
|---|---|---|
| MK-1006 DFC | DRUG | Each dry filled capsule contains 20 mg MK-1006 |
| MK-1006 FCT | DRUG | Each film coated tablet contains 40 mg of MK-1006 |
Inclusion Criteria: * is a male or a female of non-child bearing potential * has type 2 diabetes (T2D) and is either being treated with diet and exercise alone or with a single or combination oral anti-hyperglycemic agent(s) * has been a nonsmoker for at least 6 months Exclusion Criteria: * has a...